Skip to main content

Table 1 Characteristics of 99 patients accepted for treatment by gene therapy as part of their disease management

From: Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial

Case information Groupa P-value
  I (n = 35) II (n = 33) III (n = 31)  
Age, years, mean ± SDb 57.06 ± 10.63 59.79 ± 12.31 55.29 ± 10.60 0.274
Gender, n (%)c     0.953
 Male 21 (60.0) 21 (63.6) 19 (61.3)  
 Female 14 (40.0) 12 (36.4) 12 (38.7)  
Tumor classification, n (%)d     0.909
 T2 3 (8.6) 3 (9.1) 4 (12.9)  
 T3 16 (45.7) 13 (39.4) 12 (38.7)  
 T4 16 (45.7) 17 (51.5) 15 (48.4)  
UICC stage, n (%)d     0.0.996
 III 11 (31.4) 9 (27.3) 9 (29.0)  
 IVa 20 (57.1) 20 (60.6) 19 (61.3)  
 IVb 4 (11.4) 4 (12.1) 3 (9.7)  
Tumor site, n (%)e     1.000
 Tongue 13 (37.1) 11 (33.3) 12 (38.7)  
 Buccal membrane 10 (28.6) 10 (30.3) 8 (25.8)  
 Gingiva 6 (17.1) 7 (21.2) 7 (22.6)  
 Floor of mouth 3 (8.6) 2 (6.1) 2 (6.5)  
 Palate 1 (2.9) 1 (3.0) 0 (0.0)  
 Lips 2 (5.7) 2 (6.1) 2 (6.5)  
Bax expression, n (%)e     0.796
 < 1% (-) 30 (85.7) 30 (90.9) 27 (87.1)  
 10 to 25% (+) 5 (14.3) 3 (9.1) 4 (12.9)  
Bcl-2 expression, n (%)d     0.241
 <10% (-) 2 (5.7) 5 (15.2) 5 (16.1)  
 10 to 24% (+) 4 (11.4) 10 (30.3) 4 (12.9)  
 25 to 49% (++) 15 (42.9) 9 (27.3) 13 (41.9)  
 ≥50% (+++) 14 (40.0) 9 (27.3) 9 (29.0)  
Tumor grading, n (%)d     0.956
 I 5 (14.3) 3 (9.1) 2 (6.5)  
 II 14 (40.0) 15 (45.5) 15 (48.4)  
 III 16 (45.7) 15 (45.5) 14 (45.2)  
  1. aGroup I: chemotherapy and rAD-p53; group II: rAD-p53; group III: chemotherapy.
  2. P-values are based on bANOVA; cχ2; dKruskal-Wallis test, and eFisher’s exact test.